Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases
Abstract Recent Ebola outbreaks underscore the importance of continuous prevention and disease control efforts. Authorized vaccines include Merck’s Ervebo (rVSV-ZEBOV) and Johnson & Johnson’s two-dose combination (Ad26.ZEBOV/MVA-BN-Filo). Here, in a five-year follow-up of the PREVAC randomized t...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-09-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-024-51453-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849234911783813120 |
|---|---|
| author | Aurélie Wiedemann Edouard Lhomme Mélanie Huchon Emile Foucat Marion Bérerd-Camara Lydia Guillaumat Marcel Yaradouno Jacqueline Tambalou Cécile Rodrigues Alexandre Ribeiro Abdoul Habib Béavogui Christine Lacabaratz Rodolphe Thiébaut Laura Richert Yves Lévy the Prevac study team |
| author_facet | Aurélie Wiedemann Edouard Lhomme Mélanie Huchon Emile Foucat Marion Bérerd-Camara Lydia Guillaumat Marcel Yaradouno Jacqueline Tambalou Cécile Rodrigues Alexandre Ribeiro Abdoul Habib Béavogui Christine Lacabaratz Rodolphe Thiébaut Laura Richert Yves Lévy the Prevac study team |
| author_sort | Aurélie Wiedemann |
| collection | DOAJ |
| description | Abstract Recent Ebola outbreaks underscore the importance of continuous prevention and disease control efforts. Authorized vaccines include Merck’s Ervebo (rVSV-ZEBOV) and Johnson & Johnson’s two-dose combination (Ad26.ZEBOV/MVA-BN-Filo). Here, in a five-year follow-up of the PREVAC randomized trial (NCT02876328), we report the results of the immunology ancillary study of the trial. The primary endpoint is to evaluate long-term memory T-cell responses induced by three vaccine regimens: Ad26–MVA, rVSV, and rVSV–booster. Polyfunctional EBOV-specific CD4+ T-cell responses increase after Ad26 priming and are further boosted by MVA, whereas minimal responses are observed in the rVSV groups, declining after one year. In-vitro expansion for eight days show sustained EBOV-specific T-cell responses for up to 60 months post-prime vaccination with both Ad26-MVA and rVSV, with no decline. Cytokine production analysis identify shared biomarkers between the Ad26-MVA and rVSV groups. In secondary endpoint, we observed an elevation of pro-inflammatory cytokines at Day 7 in the rVSV group. Finally, we establish a correlation between EBOV-specific T-cell responses and anti-EBOV IgG responses. Our findings can guide booster vaccination recommendations and help identify populations likely to benefit from revaccination. |
| format | Article |
| id | doaj-art-8cb4eec69ef44d87a3425cc6b54f1280 |
| institution | Kabale University |
| issn | 2041-1723 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj-art-8cb4eec69ef44d87a3425cc6b54f12802025-08-20T04:02:57ZengNature PortfolioNature Communications2041-17232024-09-0115111510.1038/s41467-024-51453-zLong-term cellular immunity of vaccines for Zaire Ebola Virus DiseasesAurélie Wiedemann0Edouard Lhomme1Mélanie Huchon2Emile Foucat3Marion Bérerd-Camara4Lydia Guillaumat5Marcel Yaradouno6Jacqueline Tambalou7Cécile Rodrigues8Alexandre Ribeiro9Abdoul Habib Béavogui10Christine Lacabaratz11Rodolphe Thiébaut12Laura Richert13Yves Lévy14the Prevac study teamVaccine Research Institute, Université Paris-EstVaccine Research Institute, Université Paris-EstVaccine Research Institute, Université Paris-EstVaccine Research Institute, Université Paris-EstAlliance for International Medical ActionVaccine Research Institute, Université Paris-EstAlliance for International Medical ActionAlliance for International Medical ActionVaccine Research Institute, Université Paris-EstVaccine Research Institute, Université Paris-EstCentre National de Formation et de Recherche en Santé Rurale (CNFRSR)Vaccine Research Institute, Université Paris-EstVaccine Research Institute, Université Paris-EstVaccine Research Institute, Université Paris-EstVaccine Research Institute, Université Paris-EstAbstract Recent Ebola outbreaks underscore the importance of continuous prevention and disease control efforts. Authorized vaccines include Merck’s Ervebo (rVSV-ZEBOV) and Johnson & Johnson’s two-dose combination (Ad26.ZEBOV/MVA-BN-Filo). Here, in a five-year follow-up of the PREVAC randomized trial (NCT02876328), we report the results of the immunology ancillary study of the trial. The primary endpoint is to evaluate long-term memory T-cell responses induced by three vaccine regimens: Ad26–MVA, rVSV, and rVSV–booster. Polyfunctional EBOV-specific CD4+ T-cell responses increase after Ad26 priming and are further boosted by MVA, whereas minimal responses are observed in the rVSV groups, declining after one year. In-vitro expansion for eight days show sustained EBOV-specific T-cell responses for up to 60 months post-prime vaccination with both Ad26-MVA and rVSV, with no decline. Cytokine production analysis identify shared biomarkers between the Ad26-MVA and rVSV groups. In secondary endpoint, we observed an elevation of pro-inflammatory cytokines at Day 7 in the rVSV group. Finally, we establish a correlation between EBOV-specific T-cell responses and anti-EBOV IgG responses. Our findings can guide booster vaccination recommendations and help identify populations likely to benefit from revaccination.https://doi.org/10.1038/s41467-024-51453-z |
| spellingShingle | Aurélie Wiedemann Edouard Lhomme Mélanie Huchon Emile Foucat Marion Bérerd-Camara Lydia Guillaumat Marcel Yaradouno Jacqueline Tambalou Cécile Rodrigues Alexandre Ribeiro Abdoul Habib Béavogui Christine Lacabaratz Rodolphe Thiébaut Laura Richert Yves Lévy the Prevac study team Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases Nature Communications |
| title | Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases |
| title_full | Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases |
| title_fullStr | Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases |
| title_full_unstemmed | Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases |
| title_short | Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases |
| title_sort | long term cellular immunity of vaccines for zaire ebola virus diseases |
| url | https://doi.org/10.1038/s41467-024-51453-z |
| work_keys_str_mv | AT aureliewiedemann longtermcellularimmunityofvaccinesforzaireebolavirusdiseases AT edouardlhomme longtermcellularimmunityofvaccinesforzaireebolavirusdiseases AT melaniehuchon longtermcellularimmunityofvaccinesforzaireebolavirusdiseases AT emilefoucat longtermcellularimmunityofvaccinesforzaireebolavirusdiseases AT marionbererdcamara longtermcellularimmunityofvaccinesforzaireebolavirusdiseases AT lydiaguillaumat longtermcellularimmunityofvaccinesforzaireebolavirusdiseases AT marcelyaradouno longtermcellularimmunityofvaccinesforzaireebolavirusdiseases AT jacquelinetambalou longtermcellularimmunityofvaccinesforzaireebolavirusdiseases AT cecilerodrigues longtermcellularimmunityofvaccinesforzaireebolavirusdiseases AT alexandreribeiro longtermcellularimmunityofvaccinesforzaireebolavirusdiseases AT abdoulhabibbeavogui longtermcellularimmunityofvaccinesforzaireebolavirusdiseases AT christinelacabaratz longtermcellularimmunityofvaccinesforzaireebolavirusdiseases AT rodolphethiebaut longtermcellularimmunityofvaccinesforzaireebolavirusdiseases AT laurarichert longtermcellularimmunityofvaccinesforzaireebolavirusdiseases AT yveslevy longtermcellularimmunityofvaccinesforzaireebolavirusdiseases AT theprevacstudyteam longtermcellularimmunityofvaccinesforzaireebolavirusdiseases |